Cytokinetics (CYTK) Projected to Post Earnings on Tuesday

Cytokinetics (NASDAQ:CYTK - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of ($1.41) per share and revenue of $2.77 million for the quarter.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.03. The company had revenue of $16.93 million during the quarter, compared to analysts' expectations of $14.26 million. On average, analysts expect Cytokinetics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Cytokinetics Stock Down 18.4 %

Shares of CYTK stock traded down $7.91 during trading hours on Friday, hitting $35.01. 2,290,877 shares of the company were exchanged, compared to its average volume of 1,613,170. The business's 50-day simple moving average is $41.54 and its two-hundred day simple moving average is $46.86. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. Cytokinetics has a one year low of $32.74 and a one year high of $68.44. The stock has a market capitalization of $4.17 billion, a price-to-earnings ratio of -6.56 and a beta of 0.94.

Insiders Place Their Bets

In other Cytokinetics news, CEO Robert I. Blum sold 5,000 shares of the firm's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $40.96, for a total transaction of $204,800.00. Following the sale, the chief executive officer now directly owns 417,629 shares of the company's stock, valued at $17,106,083.84. This trade represents a 1.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Fady Ibraham Malik sold 2,000 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $48.06, for a total transaction of $96,120.00. Following the transaction, the executive vice president now directly owns 116,071 shares of the company's stock, valued at $5,578,372.26. This trade represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,360 shares of company stock valued at $3,848,445. Company insiders own 3.40% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on CYTK shares. JMP Securities reaffirmed a "market outperform" rating and set a $78.00 price objective on shares of Cytokinetics in a research note on Thursday, April 10th. HC Wainwright reaffirmed a "buy" rating and set a $120.00 price objective on shares of Cytokinetics in a research report on Monday, April 21st. Citigroup initiated coverage on Cytokinetics in a report on Friday, February 7th. They set a "buy" rating and a $86.00 price objective on the stock. Morgan Stanley set a $67.00 price target on shares of Cytokinetics in a research report on Friday, March 7th. Finally, Stifel Nicolaus started coverage on Cytokinetics in a report on Wednesday, January 22nd. They set a "buy" rating and a $80.00 target price on the stock. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Cytokinetics has a consensus rating of "Moderate Buy" and a consensus target price of $79.13.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.